7/24/2023 | SP | New Issue: JPMorgan prices $250,000 contingent interest autocallables linked to three stocks
|
8/16/2022 | IGLM | GlaxoSmithKline to redeem notes from two series due 2023
|
8/12/2022 | CV | Market Commentary: Cerevel convertible notes skyrocket on debut; GSK, Illumina unchanged in heavy volume
|
4/14/2022 | IGLM | GlaxoSmithKline elects to redeem 2.875% notes due 2022 on May 1
|
3/21/2022 | IG | New Issue: GSK prices $8.75 billion of notes in seven tranches due 2024-2052 for Haleon spinoff
|
3/18/2022 | EUIG | Investor calls underway for spinoff megadeal of Haleon from GSK
|
3/18/2022 | IG | Market Commentary: Strong high-grade supply builds; Haleon in deal pipeline; new energy, financial paper tighter
|
3/17/2022 | BKIG | Moody's rates GSK Consumer/Haleon notes Baa1
|
3/17/2022 | BKIG | S&P gives BBB to GSK Consumer/Haleon notes
|
7/2/2021 | CVIG | Moody's moves GlaxoSmithKline view to stable
|
10/7/2020 | CV | Market Commentary: Fiverr eyed, looks cheap; GSK exchangeables tied to Theravance top par; K12 improves
|
9/28/2020 | IG | New Issue: GlaxoSmithKline prices $1.25 billion of 0.534% three-year notes at 38 bps spread
|
9/28/2020 | IG | GlaxoSmithKline intends to price notes due 2023 via four bookrunners
|
6/19/2020 | CV | Market Commentary: CryoLife convertibles trade up on debut; GSK active; Allegheny sinks; One Medical gains
|
6/18/2020 | CV | Market Commentary: CryoLife on tap; GSK exchangeable trades up; Allegheny below par; U.S. Steel active
|
6/18/2020 | CV | Market Commentary: Morning Commentary: CryoLife on tap; GSK exchangeable prices rich; Allegheny trades up
|
6/18/2020 | CV | New Issue: GSK prices $280 million 0% three-year notes exchangeable for Theravance at 108.5
|
6/17/2020 | CV | Market Commentary: Allegheny Technologies, GlaxoSmithKline exchangeables eyed; Jazz, Palo Alto top par
|
6/17/2020 | CVIG | Moody’s assigns GSK Finance notes A2
|
6/17/2020 | CV | Market Commentary: Morning Commentary: Allegheny Technologies, GlaxoSmithKline exchangeables eyed
|
6/17/2020 | CV | GSK’s $300 million 0% notes due 2023 exchangeable into Theravance stock talked at 106.5-108.5
|
5/27/2020 | SP | New Issue: Morgan Stanley sells $10 million review notes tied to three stocks
|
4/7/2020 | IG | S&P trims GlaxoSmithKline
|
12/24/2019 | SP | New Issue: Credit Suisse sells $1.68 million contingent coupon autocalls on three stocks
|
11/21/2019 | SP | New Issue: Credit Suisse sells $2 million contingent coupon autocallable yield notes on pharma
|
10/4/2019 | SP | New Issue: UBS prices $3.9 million trigger autocallable contingent yield notes on stocks
|
7/30/2019 | SP | New Issue: JPMorgan prices $1.84 million contingent interest autocallables linked to pharma stocks
|
6/27/2019 | SP | New Issue: RBC sells $3.22 million contingent coupon barrier autocalls on three stocks
|
5/28/2019 | IG | Fitch lowers GlaxoSmithKline
|
3/19/2019 | IG | New Issue: GlaxoSmithKline Capital details $3.5 billion three-part sale of guaranteed notes
|
3/18/2019 | IG | Market Commentary: GlaxoSmithKline sells $3.5 billion notes; Target, SEB, utilities tap high-grade market
|
3/18/2019 | IG | New Issue: GlaxoSmithKline sells $3.5 billion of guaranteed notes in three parts
|
3/18/2019 | IG | Market Commentary: Morning Commentary: GlaxoSmithKline, Target, utilities to tap high-grade bond market
|
3/18/2019 | IG | GlaxoSmithKline Capital to price fixed- and floating-rate guaranteed notes in four tranches
|
3/12/2019 | SP | New Issue: RBC sells $100,000 contingent coupon barrier autocallables on two pharma stocks
|
2/6/2019 | SP | New Issue: RBC sells $270,000 contingent coupon barrier autocallables on two pharma stocks
|
1/22/2019 | SP | RBC plans contingent coupon barrier autocallables tied to pharma stocks
|
12/21/2018 | IG | Moody's affirms GlaxoSmithKline
|
12/6/2018 | IG | S&P lowers GlaxoSmithKline to negative
|
12/6/2018 | IG | Moody's changes GlaxoSmithKline view to negative
|
5/11/2018 | EMHYPFPV | Market Commentary: Strong high-grade supply forecast; Vodafone, ASB plan roadshows; Petrofac markets notes
|
5/11/2018 | IG | Market Commentary: Strong high-grade supply forecast; Vodafone, ASB plan roadshows; Petrofac markets notes
|
5/11/2018 | IG | Market Commentary: Morning Commentary: Investment-grade bond supply beats forecasts; inflows decline
|
5/11/2018 | IG | New Issue: GlaxoSmithKline prices $6 billion of notes in five tranches
|
5/10/2018 | EMHYPFPV | Market Commentary: Toyota, O’Reilly, Southern Gas price; HSBC, GlaxoSmithKline offer notes; Barclays improves
|
5/10/2018 | IG | Market Commentary: Toyota, O’Reilly, Southern Gas price; HSBC, GlaxoSmithKline offer notes; Barclays improves
|
5/10/2018 | IG | Market Commentary: Morning Commentary: HSBC, GlaxoSmithKline, O’Reilly deals on tap; General Dynamics notes tighten
|
5/10/2018 | IG | GlaxoSmithKline intends to sell six tranches of dollar notes
|
4/11/2018 | IG | Fitch changes GlaxoSmithKline to negative
|
3/28/2018 | IG | Moody’s affirms GlaxoSmithKline
|
2/2/2018 | SP | New Issue: RBC prices $922,000 contingent coupon barrier autocallables tied to two stocks
|
11/14/2017 | SP | New Issue: Credit Suisse prices $2.59 million 8% autocallable reverse convertibles on four pharma stocks
|
10/26/2017 | SP | New Issue: Morgan Stanley sells $3.42 million 5.52% contingent income autocalls on pharma stocks
|
7/28/2017 | IG | Moody's changes outlook on GlaxoSmithKline to stable
|
5/9/2017 | SP | BMO Harris plans digital yield generator CDs due 2022 tied to stocks
|
5/5/2017 | SP | New Issue: Barclays sells $1.9 million phoenix autocallable notes on two stocks
|
2/2/2017 | SP | New Issue: RBC prices $4.05 million direct investment notes tied to 20 stocks
|
1/9/2017 | SP | RBC plans direct investment notes linked to basket of 20 stocks
|
5/27/2016 | IG | Fitch lowers GlaxoSmithKline
|
5/29/2015 | IG | S&P affirms GlaxoSmithKline
|
5/29/2015 | IG | Moody’s lowers GlaxoSmithKline view to negative
|
4/16/2015 | SP | New Issue: Barclays prices $1.38 million seven-year notes linked to basket of ADSs
|
12/17/2014 | IG | Fitch lowers GlaxoSmithKline view to negative
|
12/2/2014 | SP | Bank of the West plans seven-year income CDs linked to five stocks
|
10/10/2014 | SP | Precidian plans unit investment trusts linked to stocks, currencies
|
8/1/2014 | IG | Moody’s lowers GlaxoSmithKline to A2
|
4/28/2014 | IG | S&P affirms GlaxoSmithKline
|
4/23/2014 | IG | Moody's could lower GlaxoSmithKline
|
7/29/2013 | IG | Moody's: GlaxoSmithKline view negative
|
3/14/2013 | IG | Market Commentary: Midday Commentary: Trading volume hits $2 billion as market mostly unchanged; Glaxo notes firm
|
3/13/2013 | IG | New Issue: GlaxoSmithKline prices $3 billion of three-, 10-, 30-year notes
|
3/13/2013 | IG | Market Commentary: GSK, Goldcorp, SEB bring bonds as issuance pace slows; recent deals mixed in secondary market
|
8/9/2012 | IG | Fitch affirms GlaxoSmithKline
|
8/1/2012 | CVLM | Human Genome announces put option, make-whole conversion adjustment
|
5/4/2012 | IG | Market Commentary: Primary empties at end of $20 billion week; more to come; spreads widen; GE Capital weaker
|
5/2/2012 | IG | New Issue: GlaxoSmithKline prices $5 billion of notes in three tranches
|
5/2/2012 | IG | Market Commentary: GSK does massive trade alongside BP, WellPoint, Ericsson, Barclays; Ericsson comes in 15 bps
|
12/20/2011 | BKHY | Prestige to finance Glaxo acquisitions with new term loan, bonds
|
11/3/2011 | IG | Fitch: GlaxoSmithKline unaffected
|
8/11/2011 | IG | Fitch affirms GlaxoSmithKline
|
3/4/2011 | IG | GlaxoSmithKline files automatic shelf registration for debt securities
|
7/6/2010 | IG | Fitch affirms GlaxoSmithKline
|
2/18/2010 | IG | Moody's: GlaxoSmithKline view to stable
|
12/31/2009 | IG | Outlook 2010: Drug companies, money managers lead 2009's notable deals
|
8/25/2009 | SS | Market Commentary: Human Genome stock up on deal talk; Venture OKs buyout bid; Syniverse likely off deal market
|
6/15/2009 | IG | Market Commentary: Deutsche Telekom, Telecom Italia, Comcast price as telecoms fill primary; bonds trader lower
|
4/23/2009 | SS | Market Commentary: Centennial buyout could let AT&T walk; Emulex auction expected; major pharma mergers predicted
|
4/22/2009 | BK | S&P affirms Stiefel
|
4/21/2009 | IG | Fitch cuts GlaxoSmithKline
|
2/19/2009 | IG | Market Commentary: New Roche bonds trade solidly higher; Snap-on prices two-part deal; CBS gains on debt-payment pledge
|
2/18/2009 | IG | Market Commentary: Roche sells mega deal, Canadian National Rail, Goodrich also price; DuPont new bonds widen
|
1/7/2009 | SS | GlaxoSmithKline completes tender offer for Genelabs
|
12/31/2008 | SS | GlaxoSmithKline extends offer for Genelabs to Jan. 6
|
12/31/2008 | IG | Outlook 2009: Issuance forecast near 2008 level; price compromise seen for 2009; Glaxo, Altria deals notable
|
12/8/2008 | SS | GlaxoSmithKline's offer for Genelabs extended to Friday
|
12/2/2008 | IG | Market Commentary: Citigroup, Goldman tap FDIC note program, Caterpillar, HP, ConEd price deals; spreads widen as Treasuries rally
|
11/12/2008 | SS | GlaxoSmithKline begins $1.30-per-share cash tender offer for Genelabs Technologies
|
10/30/2008 | SS | GlaxoSmithKline, Genelabs to combine in transaction valued at $57 million
|
6/2/2008 | SS | GlaxoSmithKline acquires 97% of Sirtris Pharmaceuticals' shares in tender offer
|
5/30/2008 | IG | Market Commentary: National Bank of Greece issues, caps week of $16 billion, record May; supply, issuance dip as yields rise
|
5/29/2008 | IG | Market Commentary: Cox Communications, BMC Software, Rentenbank price; issuance, supply dwindle at end of record month
|
5/28/2008 | IG | Market Commentary: Telecom Italia, International Paper, Cardinal Health, Nucor, Italy, AmEx price; market weakens at close
|
5/16/2008 | IG | Market Commentary: Ontario, Starwood Hotels, JPMorgan, iStar price as week tops $35 billion; record May expected
|
5/15/2008 | IG | Market Commentary: Eaton, NiSource, Deutsche Bank, Harley Davidson, HBOS price; new issue premiums continue decrease
|
5/12/2008 | IG | Market Commentary: Petro-Canada, ACE INA, Centerpoint Energy, Simon Property, Harsco, price as spreads remain tight
|
5/7/2008 | IG | Market Commentary: JPMorgan, Merrill, KeyCorp, Colgate, Coca-Cola Enterprises, Hartford, Quebec price in steady conditions
|
5/6/2008 | IG | New Issue: GlaxoSmithKline prices upsized $9 billion in four tranches
|
5/6/2008 | IG | Market Commentary: GlaxoSmithKline prices year's biggest deal; Citigroup sells two; Berkshire Hathaway, TransAlta price
|
3/4/2008 | CVIG | GlaxoSmithKline files automatic shelf registration
|
2/11/2008 | SP | New Issue: JPMorgan prices $1.38 million 9.3% reverse exchangeables linked to GlaxoSmithKline
|
11/21/2007 | SS | Market Commentary: GlaxoSmithKline shares slip on $1.65 billion Reliant merger agreement; Countrywide shares sink
|
6/8/2007 | SP | New Issue: ABN Amro sells $750,000 11.2% knock-in reverse exchangeables linked to GlaxoSmithKline
|
6/6/2007 | SS | Market Commentary: Ameritrade, E*Trade surge as Chuck slips; Nvidia gains; WCI up; Bally better; Cleveland off
|
5/21/2007 | SS | Market Commentary: Alltel may see better bid; Cytyc climbs, Hologic hit; Pioneer up; Atlas Energy advances; WCI off
|
10/27/2006 | BT | Fitch: GlaxoSmithKline can absorb repurchases
|
10/26/2006 | BT | Market Commentary: Achillion gains on debut; Cadence slips; DOV Pharma nosedives; Celgene better; Renovis falls 76%
|
10/24/2006 | BT | Fitch affirms GlaxoSmithKline
|
9/25/2006 | BT | GlaxoSmithKline epilepsy drug Lamictal approved for new indication
|
9/20/2006 | BT | GlaxoSmithKline, Pozen say Trexima offers consistent migraine relief
|
9/20/2006 | BT | Avant: GlaxoSmithKline paying only 70% of royalties on Rotarix
|
9/19/2006 | BT | Bear Stearns cuts Glaxo to underperform
|
9/18/2006 | BT | Roche, GlaxoSmithKline: Study shows women more likely to stay on Boniva for osteoporosis
|
9/18/2006 | BT | GlaxoSmithKline seeks U.S. approval for Tykerb
|
9/15/2006 | BT | GlaxoSmithKline says Avandia reduces risk of type 2 diabetes
|
9/11/2006 | BT | Vertex launches follow-on offering of 8 million shares via Merrill Lynch
|
9/7/2006 | BT | GlaxoSmithKline studies show orlistat plus diet leads to weight loss
|
9/7/2006 | BT | Minster: GlaxoSmithKline extends rights to tonabersat
|
9/5/2006 | BT | GlaxoSmithKline, Adolor report mixed results from phase 3 alvimopan studies
|
9/5/2006 | BT | GlaxoSmithKline: Requip effective in Parkinson's disease
|
9/1/2006 | BT | Market Commentary: Sanofi flu news pushes smaller biotechs lower; BioDelivery off 10%; Curis slips on R&D shift
|
8/24/2006 | BT | ChemoCentryx raises funds through GlaxoSmithKline alliance, $17.7 million round of series C financing
|
8/17/2006 | BT | Vertex, Glaxo's Lexiva provided comparable efficacy to Kaletra in study
|
8/14/2006 | BT | GlaxoSmithKline, Shionogi finish HIV clinical study
|
8/4/2006 | BT | Market Commentary: Invitrogen, CV Therapeutics plunge; Osiris debuts higher, ends steady; Adolor gets eyed
|
8/1/2006 | BT | GlaxoSmithKline's Lamictal decreases seizures in adolescents, study says
|
7/27/2006 | BT | GlaxoSmithKline seeks U.S., European marketing approval for rhinitis intranasal treatment
|
7/26/2006 | BT | GlaxoSmithKline reports advance in H5N1 flu vaccine program
|
7/24/2006 | BT | GlaxoSmithKline starts phase 3 antimalaria study in sub-Saharan Africa
|
7/21/2006 | BT | GlaxoSmithKline: study shows effectiveness of Advair plus inhaled corticosteroid in asthma treatment
|
7/20/2006 | BT | GlaxoSmithKline strikes government deal to provide Relenza for state stockpiles
|
7/12/2006 | BT | GlaxoSmithKline data suggests ASO4 for cervical cancer enhances immune system
|
7/11/2006 | BT | GlaxoSmithKline's Avandamet approved by FDA for treatment of type 2 diabetes
|
7/5/2006 | BT | New Issue: Futura raises £2.652 million in follow-on offering of 3.4 million shares at 78p
|
6/26/2006 | BT | GlaxoSmithKline, Pozen: sumatriptan effective in treating head and neck pain associated with migraines
|
6/26/2006 | BT | Market Commentary: Vasogen plunges 74%; Anadys falls 45%; Nastech, Amylin gain on pact; Neurocrine finds buyers
|
6/19/2006 | BT | Cytokinetics, GlaxoSmithKline extend research collaboration
|
6/19/2006 | BT | GlaxoSmithKline data shows eltrombopag raises platelet count
|
6/15/2006 | BT | GlaxoSmithKline's Hycamtin approved to treat cervical cancer in combination chemotherapy
|
6/12/2006 | BT | GlaxoSmithKline: Data shows benefits of Avandaryl in patients with type 2 diabetes
|
6/12/2006 | BT | FDA approves Wellbutrin XL for prevention of seasonal major depressive episodes
|
6/9/2006 | BT | Pozen, Glaxo may conduct more studies of investigational migraine treatment Trexima
|
6/9/2006 | BT | Market Commentary: Pozen plunges after FDA setback; NxStage climbs after follow-on; BioNumerik nixes IPO plans
|
6/7/2006 | BT | GlaxoSmithKline, Galapagos to collaborate on osteoarthritis drugs
|
6/6/2006 | BT | GlaxoSmithKline says MAGE-A3 reduces relative cancer risk by 33%
|
6/5/2006 | BT | GlaxoSmithKline says Tykerb doubles time to progression for breast cancer patients
|
6/5/2006 | BT | GlaxoSmithKline's cervical cancer vaccine highly immunogenic, well-tolerated in trial
|
6/5/2006 | BT | GlaxoSmithKline licenses cancer antigen portfolio
|
5/31/2006 | BT | Adolor: FDA accepts response to Entereg NDA letter
|
5/19/2006 | BT | Flamel Technologies gets $1 million milestone payment
|
5/17/2006 | BT | GlaxoSmithKline data shows Coreg CR reduces blood pressure
|
5/4/2006 | BT | GlaxoSmithKline, Adolor alvimopan study shows improvement in opioid use-related GI symptoms
|
5/4/2006 | BT | HHS awards more than $1 billion to five pharmaceutical companies to develop flu vaccines
|
5/4/2006 | BT | Sirna, GlaxoSmithKline to pursue RNAi-based therapeutics
|
5/2/2006 | BT | NPS, GlaxoSmithKline announce clinical advancement of calcilytics program
|
4/13/2006 | BT | GlaxoSmithKline, Adolor fill trial studying Entereg for gastrointestinal pain of opioids ahead of target
|
4/11/2006 | BT | GlaxoSmithKline: Enzyme may predict risk of future cardiovascular events
|
4/10/2006 | BT | Praecis, GlaxoSmithKline form agreement to identify small molecule drug candidates
|
4/6/2006 | BT | GlaxoSmithKline drug Arixtra comparable to Lovenox, study says
|
4/5/2006 | BT | GlaxoSmithKline data of Cervarix shows 100% efficacy
|
4/5/2006 | BT | GlaxoSmithKline, Pozen say one tablet combats vascular, neurological causes of migraine
|
4/3/2006 | BT | GlaxoSmithKline, Sirna form alliance for RNAi-based respiratory therapies
|
4/3/2006 | BT | GlaxoSmithKline stops enrollment in phase 3 trial of Tykerb for breast cancer after meeting endpoint
|
3/30/2006 | BT | GlaxoSmithKline begins human trial program with two H5N1 pandemic flu vaccines
|
3/30/2006 | BT | GlaxoSmithKline, Pharmacopeia to collaborate on drug discovery
|
3/29/2006 | BT | GlaxoSmithKline's Relenza gets FDA approval for flu prevention
|
3/28/2006 | BT | GlaxoSmithKline: Study shows Seretide reduces mortality in patients with pulmonary disease
|
3/23/2006 | BT | GlaxoSmithKline submits Biologics License Application for FDA approval of FluLaval
|
3/23/2006 | BT | GlaxoSmithKline says research shows elephantiasis could be eliminated
|
3/23/2006 | BT | GlaxoSmithKline's Flovent HFA asthma inhaler approved by FDA for use in children
|
3/17/2006 | BT | New Roche, GlaxoSmithKline study shows women with osteoporosis say Boniva is more convenient
|
3/14/2006 | BT | GlaxoSmithKline: Research shows Arixtra superior to standard acute coronary syndrome therapy
|
2/17/2006 | BT | GlaxoSmithKline's FDA application accepted for Hycamtin, granted priority review
|
2/14/2006 | BT | GlaxoSmithKline begins eltrombopag phase 3 trial in adults with blood disorder
|
2/14/2006 | BT | Pliva reaches agreement with GlaxoSmithKline, exits from proprietary business
|
2/14/2006 | BT | GlaxoSmithKline's retapamulin antibiotic NDA accepted for review by FDA
|
2/13/2006 | BT | GlaxoSmithKline reports pivotal study shows reduced risk of venous thromboembolism
|
2/9/2006 | BT | Market Commentary: Acorda IPO on deck with cheaper talk; Serono up on Glaxo chatter; Amylin soars; Charles River rises
|
2/3/2006 | BT | Results of GlaxoSmithKline trial indicate Arixtra prevents venous thromboembolism
|
2/2/2006 | BT | FDA approves GlaxoSmithKline's Imitrex injection
|
2/1/2006 | BT | GlaxoSmithKline announces approval, availability of Avandaryl for diabetes
|
1/27/2006 | BT | Market Commentary: Arena up after follow-on; Altus interest grows; Nektar, Pfizer up; Glaxo gains on Gates' TB pledge; Teva prices
|
1/23/2006 | BT | Roche, GlaxoSmithKline get FDA committee support for over-the-counter orlistat for weight loss
|
1/10/2006 | BT | Human Genome gets $5 million milestone from GlaxoSmithKline for diabetes drug candidate
|
1/6/2006 | BT | FDA approves Roche, GlaxoSmithKline's Boniva, first intravenous treatment for postmenopausal osteoporosis
|
1/4/2006 | BT | Studies show GlaxoSmithKline rotavirus vaccine candidate effective against disease
|
1/3/2006 | BT | Bayer HealthCare buys European marketing rights for telmisartan from GlaxoSmithKline
|
1/3/2006 | BT | GlaxoSmithKline study shows Requip improves symptoms on Restless Legs Syndrome
|
12/19/2005 | BT | MediGene signs license deal with Glaxo for patents to develop therapeutic tumor vaccine
|
12/19/2005 | BT | GlaxoSmithKline says retapamulin lab studies show potency against skin-infection pathogens
|
12/16/2005 | BT | GlaxoSmithKline, Vertex's brecanavir suppresses HIV levels, study says
|
12/13/2005 | BT | Cytokinetics says GlaxoSmithKline selected third development candidate under alliance
|
12/13/2005 | BT | Vertex could receive up to $405 million under VX-409 development deal with GlaxoSmithKline
|
12/12/2005 | BT | Fitch affirms GlaxoSmithKline
|
12/9/2005 | BT | GlaxoSmithKline begins phase 2 trial of Tykerb in cancer patients
|
12/9/2005 | BT | GlaxoSmithKline: FDA committee will review over-the-counter Xenical next month
|
12/2/2005 | BT | Ligand, GlaxoSmithKline drug eltrombopag ups platelet count, study shows
|
11/28/2005 | BT | Market Commentary: Merck pressures biotech sector; Amgen, Genentech lead slide; Enzon, BioCryst, Pozen up a tad
|
11/10/2005 | BT | GlaxoSmithKline study shows competitor Effexor XR worsens sexual function of depressed patients
|
11/1/2005 | BT | Human Genome Science study shows safety of HGS-ETR1, GlaxoSmithKline to co-develop
|
11/1/2005 | BT | GlaxoSmithKline: HPV 16/18 L1 vaccine with AS04 induces strong immune response
|
10/31/2005 | BT | GlaxoSmithKline, Malaria Vaccine Initiative receive $107.6 million Gates grant for malaria vaccine
|
10/28/2005 | BT | GlaxoSmithKline gets accelerated OK of chemotherapy Arranon
|
9/7/2005 | BT | GlaxoSmithKline to acquire ID Biomedical for C$35 per share
|
9/7/2005 | BT | Market Commentary: ID Biomedical climbs 13% on Glaxo acquisition; Chiron still rising; Nektar zooms over 10%
|
8/31/2005 | BT | Market Commentary: MedImmune shoots up over 10%; Chiron little changed; Glaxo gains on U.S. flu shot OK; Oscient flat
|
8/26/2005 | BT | GlaxoSmithKline rated market perform by Leerink Swann
|